TY - JOUR
T1 - Updated long-term outcomes after carbon-ion radiotherapy for primary renal cell carcinoma
AU - the Working Group for Genitourinary Tumors
AU - Kasuya, Goro
AU - Tsuji, Hiroshi
AU - Nomiya, Takuma
AU - Makishima, Hirokazu
AU - Haruyama, Yasuo
AU - Kobashi, Gen
AU - Ebner, Daniel K.
AU - Hayashi, Kazuhiko
AU - Omatsu, Tokuhiko
AU - Kishimoto, Riwa
AU - Yasuda, Shigeo
AU - Igarashi, Tatsuo
AU - Oya, Mototsugu
AU - Akakura, Koichiro
AU - Suzuki, Hiroyoshi
AU - Ichikawa, Tomohiko
AU - Shimazaki, Jun
AU - Kamada, Tadashi
N1 - Funding Information:
Funding information This work was supported by the Research Project for Heavy Ions at the National Institute of Radiological Sciences, Japan. We wish to express our deep appreciation to the members of the working goup for Genitourinay Tumors.
Publisher Copyright:
© 2018 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
PY - 2018/9
Y1 - 2018/9
N2 - Long-term oncological outcomes for primary renal cell carcinoma (RCC) treated with carbon-ion radiotherapy (CIRT) are poorly understood. Patients with primary RCC were treated with 12 or 16-fraction CIRT at The Hospital of the National Institute of Radiological Sciences outside of clinical trials. Outcome data were pooled and retrospectively analyzed for toxicity, local control, and disease-free, cancer-specific, and overall survival. From 1997 to 2014, 19 RCC patients (11 with T1aN0M0, 4 with T1bN0M0, and 4 with inoperable advanced stage [T4N0M0, T3aN1M0, and T1aN0M1]) were treated with CIRT and followed up for a median of 6.6 (range, 0.7-16.5) years; 9 of these patients were inoperable because of comorbidities or advanced-stage disease. Diagnoses were confirmed by imaging in 11 patients and by biopsy in the remaining 8. In 4 of 5 patients with definitive renal comorbidities, including diabetic nephropathy, sclerotic kidney or solitary kidney pre-CIRT progressed to grade 4 chronic kidney disease (CKD). In contrast, the remaining 14 patients without definitive renal comorbidities did not progress to grade 3 or higher CKD. Furthermore, although 1 case of grade 4 dermatitis was observed, there were no other grade 3 or higher non-renal adverse events. Local control rate, and disease-free, cancer-specific, and overall survival rates at 5 years of all 19 patients were 94.1%, 68.9%, 100%, and 89.2%, respectively. This updated retrospective analysis based on long-term follow-up data suggests that CIRT is a safe treatment for primary RCC patients without definitive renal comorbidities pre-CIRT, and yield favorable treatment outcomes, even in inoperable cases.
AB - Long-term oncological outcomes for primary renal cell carcinoma (RCC) treated with carbon-ion radiotherapy (CIRT) are poorly understood. Patients with primary RCC were treated with 12 or 16-fraction CIRT at The Hospital of the National Institute of Radiological Sciences outside of clinical trials. Outcome data were pooled and retrospectively analyzed for toxicity, local control, and disease-free, cancer-specific, and overall survival. From 1997 to 2014, 19 RCC patients (11 with T1aN0M0, 4 with T1bN0M0, and 4 with inoperable advanced stage [T4N0M0, T3aN1M0, and T1aN0M1]) were treated with CIRT and followed up for a median of 6.6 (range, 0.7-16.5) years; 9 of these patients were inoperable because of comorbidities or advanced-stage disease. Diagnoses were confirmed by imaging in 11 patients and by biopsy in the remaining 8. In 4 of 5 patients with definitive renal comorbidities, including diabetic nephropathy, sclerotic kidney or solitary kidney pre-CIRT progressed to grade 4 chronic kidney disease (CKD). In contrast, the remaining 14 patients without definitive renal comorbidities did not progress to grade 3 or higher CKD. Furthermore, although 1 case of grade 4 dermatitis was observed, there were no other grade 3 or higher non-renal adverse events. Local control rate, and disease-free, cancer-specific, and overall survival rates at 5 years of all 19 patients were 94.1%, 68.9%, 100%, and 89.2%, respectively. This updated retrospective analysis based on long-term follow-up data suggests that CIRT is a safe treatment for primary RCC patients without definitive renal comorbidities pre-CIRT, and yield favorable treatment outcomes, even in inoperable cases.
KW - adverse event
KW - carbon-ion radiotherapy
KW - local control
KW - renal cell carcinoma
KW - survival
UR - http://www.scopus.com/inward/record.url?scp=85052804060&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85052804060&partnerID=8YFLogxK
U2 - 10.1111/cas.13727
DO - 10.1111/cas.13727
M3 - Article
C2 - 29981249
AN - SCOPUS:85052804060
VL - 109
SP - 2873
EP - 2880
JO - Cancer Science
JF - Cancer Science
SN - 1347-9032
IS - 9
ER -